Pharmacodynamics of antivirals

Antimicrobial Pharmacodynamics in Theory and Clinical Practice, Second Edition

Volumn , Issue , 2007, Pages 295-314

  Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955542831     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (31)

1. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158:831-847.
2. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483-490.
3. Louie A, Kaw P, Lui W, Jumbe N, Miller MH, Drusano GL. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001; 45:845-851.
4. Bilello JA, Eiseman JL, Standiford HC, Drusano GL. Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrob Agents Chemother 1994; 38:628-631.
5. Biello JA, Kort JJ, MacAuley C, Fredrickson TN, Yetter RA, Eiseman JL. ZDV delays but does not prevent the transmission of MAIDS by LP-BM% MuLV-infected macrophage-monocytes. J Acquir Immune Defic Syndr 1992; 5:571-576.
6. Bilello JA, Bilello PA, Stellrecht K, et al. The uptake and anti-HIV activity of A 80987, an inhibitor of the HIV-1 protease, is reduced by human serum 1-acid glycoprotein. Antimicrob Agents Chemother 1996; 40:1491-1497.
7. Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL. The effect of 2,3-di-deoxy-2,3++didhydrothymidine (D4T) in an in vitro hollow fiver pharmacodynamic model system correlates with results of dose ranging clinical studies. Antimicrob Agnes Chemother 1994; 38:1386-1391.
8. Browne MJ, Mayer KH, Chafee SB, et al. 2',3' didehydro-3'-deoxythymidine (d4T') in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993; 167:21-29.
9. Bilello JA, Bilello PA, Kort JJ, Dudley MN, Leonard J, Drusano GL. Efficacy of constant infusion of A 77003, an inhibitor of the HIV protease in limiting acute HIV-1 infection in vitro. Antimicrob Agents Chemother 1995; 39:2523-2527.
10. Reedijk M, Boucher CA, van Brommel T, et al. Safety, pharmacokinetics and antiviral activity of A77002, a C2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1995; 39:1559-1564.
11. Preston SL, Piliero PJ, Bilello JA, Stein DS, Symonds WT, Drusano GL. In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours. Antimicrob Agents Chemother 2003; 47:3393-3399.
12. Drusano GL, Bilello JA, Preston SL, et al. Hollow fiber unit evaluation of new human immunodeficiency virus (HIV)-1 protease inhibitor, BMS232632, for determination of the linked pharmacodynamic variable. J Infect Dis 2000; 183:1126-1129.
13. Drusano GL, D'Argenio DZ, Symonds W, et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 1998; 42:2153-2159.
14. Drusano GL, D'Argenio DZ, Preston SL, et al. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother 2000; 44:1655-1659.
15. Drusano GL, Yuen GJ, Lambert JS, Seidlin M, Dolin R, Valentine FT. Quantitative relationships between dideoxyinosine exposure and surrogate markers of response in a phase I trial. Ann Intern Med 1992; 116:562-566.
16. Drusano GL, Balis FM, Gitterman SR, Pizzo PA. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemother 1994; 8:1726-1731.
17. Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine and stavudine in human immunodeficiency virus-infected children receiving combination chemotherapy. Antimicrob Agents Chemother 2000; 44:1029-1034.
18. Kozal MJ, Kroodsma K, Winters MA, et al. Didanosine resistance in HIV-infected patients switching from zidovudine to didanosine monotherapy. Ann Intern Med 1994; 121:263-268.
19. Stein DS, Drusano GL. Modeling of the change in CD4 lymphocyte cell counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir. Antimicrob Agents Chemother 1997; 41:449-453.
20. Drusano GL, Stein DS. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes introduced by the protease inhibitor indinavir. Antimicrob Agents Chemother 1998; 42:359-361.
21. Shapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996; 124:1039-1050.
22. Stein DS, Fish DG, Bilello JA, et al. A 24 week open label phase I evaluation of the HIV protease inhibitor MK-639. AIDS 1996; 10:485-492.
23. Drusano GL, Sadler BM, Millars J, et al. and the 141W94 International Product Development Team. Pharmacodynamics of 141W94 as determined by short term change in HIV RNA: Influence of viral isolate baseline EC-50 [abstr A-16]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, Sept 28-Oct 1, 1997.
24. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9-F14.
25. Drusano GL, Bilello JA, Stein DS, et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis 1998; 178:360-367.
26. Snyder S, D'Argenio DZ, Weislow O, Bilello JA, Drusano GL. The triple combination indinavir, zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother 2000; 44:1051-1058.
27. Holder DJ, Condra JH, Schleif WA, Chodakewitz J, Emini EA. Virologic failure during combination therapy with crixivan and RT inhibitors is often associated with expression of resistance-associated mutations in RT only. Conf Retroviruses Opportun Infect 1999; 6:160 [abstr 492].
28. Burger DM, Hoetelmans RMW, Hugen PWH, et al. Low Plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir containing triple therapy. Antiviral Ther 1998; 3:215-220.
29. Hoefnagel JG, Koopmans PP, Burger DM, Schurman R, Galama JM. Role of inhibitory quotient in HIV Therapy. Antivir Ther 2005; 10:879-892.
30. Drusano GL, Aweeka F, Gambertoglio J, et al. Relationship between foscarnet exposure, baseline cytomegalovirus retinitis in HIV-positive patients. AIDS 1996; 10:1113-1119.
31. Zhou Z, Rodman JH, Flynn PM, Robbins BL, Wilcox CK, D'Argenio DZ. Model for intra-cellular lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother 2006; 2686-2694.